Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT07220252 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT07220252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07220252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 1, 2026
Completion date
June 30, 2033
Enrollment
240 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis